Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-021604
Filing Date
2025-02-14
Accepted
2025-02-14 18:36:15
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 14535
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 253570
  Complete submission text file 0000950170-25-021604.txt   365923
Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

EIN.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306
Business Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306 650-507-0669
180 Life Sciences Corp. (Subject) CIK: 0001690080 (see all company filings)

EIN.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90013 | Film No.: 25631713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)